TheStreet upgraded Phibro Animal Health Corp (NASDAQ:PAHC) to Buy in a report released today.
- Updated: October 3, 2016
TheStreet has upgraded Phibro Animal Health Corp (NASDAQ:PAHC) to Buy in a report released on 9/30/2016.
Just yesterday Phibro Animal Health Corp (NASDAQ:PAHC) traded 0.18% higher at $27.23. Phibro Animal Health Corp’s 50-day moving average is $24.59 and its 200-day moving average is $22.05. The last stock price is up 23.46% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 154,213 shares of PAHC traded hands, up from an average trading volume of 128,277
Recent Performance Chart
Phibro Animal Health Corp has 52 week low of $16.80 and a 52 week high of $35.69 with a PE ratio of 13.15 and has a market capitalization of $0.
In addition to TheStreet reporting its stock price target, a total of 5 brokerages have issued a ratings update on the company. The average stock price target is $35.00 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, zero analysts rating the company a underperform, and lastly zero analysts rating the company a sell.
More About Phibro Animal Health Corp (NASDAQ:PAHC)
Phibro Animal Health Corporation (Phibro) is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company offers various products, which include Animal health products, such as antibacterials, anticoccidials, vaccines, nutritional specialty products and mineral nutrition products. The Company also manufactures and markets specific ingredients for use in the personal care, automotive, industrial chemical and chemical catalyst industries. The Company's Medicated Feed Additives (MFAs) and other business consist of concentrated medicated products, which are administered through animal feeds. The Company's MFAs and other business consists of the production and sale of antibacterials, including Stafac, Terramycin, Neo-Terramycin and Mecadox and anticoccidials, including Nicarb, Aviax, Aviax Plus, Coxistac and amprolium.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.